Cancer-specific activation of the survivin promoter and its potential use in gene therapy

Cancer Gene Therapy

Volumn 11, Issue 11, 2004, Pages 740-747

  Chen, Jin Shing ^a,b   Liu, Jaw Ching ^a   Shen, Lei ^a,c   Rau, Kung Ming ^a,d   Kuo, Hsu Ping ^a   Li, Yan M ^a   Shi, Daren ^c   Lee, Yung Chie ^b   Chang, King Jen ^b   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Liposome; Lung cancer; Promoter; Survivin

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CHOLESTEROL; DNA; LIPOSOME; LUCIFERASE; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIK GENE; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE;

BASE SEQUENCE; DNA PRIMERS; GENE THERAPY; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PLASMIDS; PROMOTER REGIONS (GENETICS); TRANSFECTION; TRANSGENES;

ANIMALIA; CYTOMEGALOVIRUS;

EID: 8444253006     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700752     Document Type: Article

References (36)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistic, 1997. CA Cancer J Clin. 1997;47:5-27.
2. Templeton NS, Lasic DD, Frederik PM, et al. Improved DNA:liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997;15:647-652.
3. Ramesh R, Saeki T, Templeton NS, et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Therapy. 2001;3:337-350.
4. Gibbs JB. Mechanism based target identification and drug discovery in cancer research. Science. 2000;287:1969-1973.
5. Robertson MW, Wang M, Siegal GP, et al. Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinomal cells. Cancer Gene Ther. 1998;5:331-336.
6. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
7. Tamm I, Wang Y, Sausville E, et al. IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas(CD95). Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315-5320.
8. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 2001;7:542-547.
9. Monzo M, Resell R, Felip E, et al. A novel anti-apoptosis gene: re-expression of Survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin Oncol. 1999;17:2100-2104.
10. Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early-stage non-small cell lung cancer. J. Pathol. 2003;200:620-626.
11. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127-134.
12. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by Survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071-5074.
13. Lu CD, Altieri DC, Tanigawa N, Expression of a novel anti-apoptosis gene, Survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808-1812.
14. Kato J, Kuwabara Y, Mitani M, et al. Expression of Survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95: 92-95.
15. Satoh K, Kaneko K, Hirota M, et al. Expression of Survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92:271-278.
16. Swana HS, Grossman D, Anthony JN, et al. Tumor content of the anti-apoptosis molecule Survivin and recurrence of bladder cancer. New Engl J Med. 1999;341:452-453.
17. Saitoh Y, Yaginuma Y, Ishikawa M. Analysis of Bcl-2, Bax, and Survivin genes in uterine cancer. Int J Oncol. 1999; 15:137-141.
18. Yoshida H, Ishiko O, Sumi T, et al. Survivin, Bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell-and serous-type ovarian carcinomas. Int J Oncol. 2001;19:537-542.
19. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, Survivin, in human melanoma. J Invest Dermatol. 1999;113:1076-1081.
20. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of Survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921-1925.
21. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of Survivin in de novo acute myeloid leukemia. Br J Haematol. 2000;111:196-203.
22. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J. 1999;344:305-311.
23. Bao R, Connolly DC, Murphy M, et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst. 2002;94:522-528.
24. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet. 1999;23:387-388.
25. Hofmann HS, Simm A, Hammer A, et al. Expression of inhibitors of apoptosis (IAP) proteins in non-small cell lung cancer. J Cancer Res Clin Oncol. 2002;128: 554-560.
26. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting Survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000;60:2805-2809.
27. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a Survivin mutant adenovirus. J Clin Invest. 2001;108: 981-990.
28. Altieri DC. Validating Survivin as a cancer therapeutic target. Nature Rev Cancer. 2003;3:46-54.
29. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322-1326.
30. Han J, Sabbatini P, White E. Induction of apoptosis by human Bbk/Bik, a BH3-containing protein that interacts with E1B 19K. Mol Cell Biol. 1996;16:5857-5864.
31. Zou Y, Peng H, Zhou B, et al. Systemic tumor suppression by the proapoptotic gene Bik. Cancer Res. 2002;62: 8-12.
32. Li YM, Wen Y, Ding QQ, Zhou BP, Hung MC. Enhancement of Bik anti-tumor effect by Bik mutants. Cancer Res. 2003;63:7630-7633.
33. Lee CM, Lo HW, Shao RP, et al. Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. Cancer Res. 2004;64:1788-1793.
34. Cao H, Stamatoyannopoulos G, Jung M. Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood. 2004;103:701-709.
35. Kircheis R, Ostermann E, Wolschek MF, et al. Tumor-targeted gene delivery of tumor necrosis factor-α induces tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther. 2002;9:673-680.
36. Tanyi JL, Lapushin R, Eder A, et al. Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. Gynecol Oncol. 2002;85:451-458.